Multiple sclerosis patients show lower bioavailable 25(OH)D and 1,25(OH)2D, but no difference in ratio of 25(OH)D/24,25(OH)2D and FGF23 concentrations

Mariska C. Vlot, Laura Boekel, Jolijn Kragt, Joep Killestein, Barbara M. van Amerongen, Robert de Jonge, Martin Den Heijer, Annemieke C. Heijboer*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Vitamin D (VitD) insufficiency is common in multiple sclerosis (MS). VitD has possible anti-inflammatory effects on the immune system. The ratio between VitD metabolites in MS patients and the severity of the disease are suggested to be related. However, the exact effect of the bone-derived hormone fibroblast-growth-factor-23 (FGF23) and VitD binding protein (VDBP) on this ratio is not fully elucidated yet. Therefore, the aim is to study differences in total, free, and bioavailable VD metabolites and FGF23 between MS patients and healthy controls (HCs). FGF23, vitD (25(OH)D), active vitD (1,25(OH)2D), inactive 24,25(OH)D, and VDBP were measured in 91 MS patients and 92 HCs. Bioavailable and free concentrations were calculated. No difference in FGF23 (p = 0.65) and 25(OH)D/24.25(OH)2D ratio (p = 0.21) between MS patients and HCs was observed. Bioavailable 25(OH)D and bioavailable 1.25(OH)2D were lower (p < 0.01), while VDBP concentrations were higher in MS patients (p = 0.02) compared with HCs, specifically in male MS patients (p = 0.01). In conclusion, FGF23 and 25(OH)D/24.25(OH)2D did not differ between MS patients and HCs, yet bioavailable VitD concentrations are of potential clinical relevance in MS patients. The possible immunomodulating role of VDBP and gender-related differences in the VD-FGF23 axis in MS need further study.

Original languageEnglish
Article number2774
JournalNutrients
Volume11
Issue number11
DOIs
Publication statusPublished - 1 Nov 2019

Cite this